USA – FDA updates guidance on promotional labeling and advertising of biosimilars

The US Food and Drug Administration (FDA) has published revised guidance on promotional labeling and advertising for prescription biosimilar drugs and their reference products. The agency issued the draft guidance – Promotional labeling and advertising considerations for prescription biological reference products, biosimilar products, and interchangeable biosimilar products: Questions and answers – on 24 April and will accept comments through 25 June. The document was designed to address ind...